Clinical Policy: Naloxegol (Movantik)
Customize your policy alerts
Sign up for Arizona Complete Health Policy AZ.CP.PMN.171 alerts
Get alerted when Policy AZ.CP.PMN.171 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage of Movantik (naloxegol) for Arizona Medicaid members, primarily for opioid-induced constipation in adults receiving chronic opioid therapy. It specifies initial and continued-therapy criteria, documentation requirements, dosing limits, exclusions, and approval durations.
The 4Q 2020 annual review reported no significant changes and updated the references.
The policy added Care1st branding and language specifying that the criteria also apply to Care1st.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.